rngen has made significant strides in our journey toward innovative drug development, marked by key milestones and achievements. Our rigorous clinical trials and collaborations with industry leaders have strengthened our position in the market. We are proud to highlight our progress in advancing therapies that address critical health issues affecting diverse populations.

rngen is committed to developing first-in-class therapies that address significant unmet medical needs in pulmonary, neurological, and hematological diseases. Our progress to date reflects our scientific rigor, strategic execution, and ability to attract funding and partnerships to advance our drug candidate, KYC and associated candidate library, towards clinical trials. The following milestones demonstrate rngen’s track record of innovation, regulatory progress, and corporate growth, reinforcing the company’s credibility to investors and potential strategic partners.

Early-Stage Development

  • Company Formation & Vision: Established as an innovative vPharma with a capital-efficient business model to accelerate drug discovery and development.
  • Initial Research & Scientific Foundation: Focused on inflammation and oxidative stress as core drivers of multiple diseases, leading to the identification of our lead drug candidate, KYC.
  • Non-Dilutive Grant Funding Success: Successfully secured multiple NIH SBIR grants from agencies such as NHLBI and NINDS, reducing early-stage investment risk and validating our approach.
  • Strategic Collaborations: Established key partnerships with leading academic institutions and contract research organizations (CROs) to support drug development efforts, see our vPharma Network (vPN)

Scientific and Preclinical Achievements

  • Discovery & Optimization of KYC: Identified and refined KYC as a systems chemico-pharmacology drug (SCPD) with a unique mechanism of action targeting inflammatory and oxidative stress pathways.
  • Preclinical Validation in Multiple Disease Models:
    • Sickle Cell Disease (SCD): Demonstrated improvements in red blood cell rheology and inflammation reduction in Townes SCD mice.
    • Bronchopulmonary Dysplasia (BPD) and Neonatal Respiratory Distress Syndrome (NRDS): Preclinical studies showed promising efficacy in reducing oxidative damage and lung inflammation in neonatal models.
    • Traumatic Brain Injury (TBI) and Chronic Traumatic Encephalopathy (CTE): Evidence of neuroprotective effects and reduction in secondary brain injury in animal models.
  • Mechanism of Action Validation: Confirmed KYC’s ability to reduce MPO-driven oxidative stress, thiylate Keap1 leading to Nrf2 activation, and modulate inflammatory pathways in disease models.
  • Publications & Scientific Recognition:
    • Peer-reviewed articles published in high-impact journals validating the scientific rationale behind KYC.
    • Presentations at international conferences such as AHA, ASH, ATS, and neuroscience-related meetings, gaining recognition from the broader scientific and medical communities.
    • See News Section for details

Regulatory and Manufacturing Progress

  • IND-Enabling Studies: Ongoing toxicology, pharmacokinetic (PK), and pharmacodynamic (PD) studies to support IND filings for multiple indications (SCD, BPD, NRDS) in 2026.
  • Pre-IND FDA Engagement: Early discussions with regulatory agencies to refine clinical development plans and optimize the regulatory pathway for accelerated approval.
  • Manufacturing Scale-Up:
    • Engaged Contract Manufacturing Organizations (CMOs) for Good Manufacturing Practice (GMP) production of KYC.
    • Advanced process development for large-scale synthesis to ensure clinical-grade supply for Phase 1 trials.
  • Intellectual Property & Patent Protection:
    • Multiple patent filings covering KYC composition, mechanism of action, and therapeutic applications.
    • Ongoing strategy to expand IP portfolio and secure long-term exclusivity.

Corporate Growth and Strategic Partnerships

  • Management Team Expansion: Recruited key industry experts in drug development, regulatory strategy, and commercialization.
  • Industry Collaborations: Engaged with leading pharmaceutical companies for potential licensing and co-development opportunities.
  • Successful Fundraising:
    • Raised significant non-dilutive NIH SBIR grant funding to support preclinical development.
    • Ongoing Series A fundraising efforts targeting $12.5 million to advance KYC into clinical trials.
  • Investor & Partner Engagement: Ongoing discussions with venture capital firms, strategic investors, and major pharmaceutical companies interested in neurology, hematology, and pulmonology.